Lung Cancer Drug Elicits Unprecedented Results in New Trial
With lung cancer being the leading cause of cancer-related deaths worldwide, news of the unprecedented success of a new drug is sure to be celebrated. The five-year results of a phase III trial present the longest progression-free survival data ever reported when treating non-small cell lung cancer (NSCLC) with a single targeted intervention. Called lorlatinib, […]
The post Lung Cancer Drug Elicits Unprecedented Results in New Trial appeared first on Good News Network.
from All News Archives – Good News Network https://ift.tt/7nx3W4H